Home|Prescribing Information|Contact Us|Site Map
Links

The following websites are good sources of information about CPP and other health issues that affect children. Remember, it is always best to talk personally with your child’s doctor and other healthcare professionals.

Lawson Wilkins Pediatric Endocrine Society
www.lwpes.org

A society of more than 900 members who work in pediatric endocrinology, LWPES is dedicated to the research and treatment of endocrine disorders and provides continuing education to its membership.

The Magic Foundation
www.magicfoundation.org

Major Aspects of Growth in Children (MAGIC) is a national nonprofit organization that provides support services for families whose children have growth hormone deficiency or CPP, as well as a wide variety of other medical conditions, which affect their growth.

The Mayo Clinic
www.mayoclinic.com

The famed Mayo Clinic website provides reliable health information written in nontechnical language on many diseases and conditions, drugs, treatment decisions, and much more.

Web MD
www.webmd.com

This extensive Internet site offers expert, comprehensive information covering a wide variety of wellness and lifestyle issues, diseases, and conditions, plus physician and hospital locations. Web MD also offers weekly, biweekly, and specialty newsletters on specific topics.

The CARES Foundation
www.caresfoundation.org

The Foundation reaches out to families and individuals with congenital adrenal hyperplasia (CAH), a family of rare inherited disorders affecting the adrenal glands. The Foundation offers personal support, educational conferences, newsletters, and a physician referral service.

Register with SUPPRELIN LA

Indication

SUPPRELIN® LA (histrelin acetate) implant is used for the treatment of children with central precocious puberty (CPP).

Important Safety Information

SUPPRELIN LA should not be used by women who are or may become pregnant, and in patients who are allergic to gonadotropin releasing hormone (GnRH) or GnRH agonist analogs. Safety and effectiveness in children under 2 years of age has not been determined.

SUPPRELIN LA, like other GnRH agonists, may cause a temporary increase in the blood levels of specific hormones associated with the onset of puberty (estrogen in girls and testosterone in both sexes) during the first week of treatment. This increase may temporarily worsen puberty symptoms during the first week, additionally, you may see new symptoms appear during this period. Within the 4 weeks of treatment with SUPPRELIN LA, hormonal suppression generally occurs and the physical signs of puberty should decrease.

Your doctor should monitor the levels of specific hormones associated with puberty progression, 1 month after starting SUPPRELIN LA and then every 6 months thereafter. Every 6-12 months, height and bone age should be also monitored by your doctor.

During the clinical trial testing of SUPPRELIN LA, the most common side effects involved the implant site and included temporary bruising, pain, soreness, redness of the skin and swelling.

Please talk with your doctor for more information or if you have any questions.

Endo Pharmaceuticals
Rx Only
© 2010 Endo Pharmaceuticals. All rights reserved.
SUPPRELIN® LA is a registered trademark of Endo Pharmaceuticals.
SP-1007/June 2009

Privacy/Legal
Intended for U.S. Residents Only